Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 256 to 270 of 2548 results for methods

  1. Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]

    Awaiting development Reference number: GID-TA10684 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]

    Awaiting development Reference number: GID-TA10685 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]

    Awaiting development Reference number: GID-TA10715 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]

    Awaiting development Reference number: GID-TA10717 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]

    Awaiting development Reference number: GID-TA10723 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]

    Awaiting development Reference number: GID-TA10916 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]

    Awaiting development Reference number: GID-TA10694 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Alere Afinion CRP for C-reactive protein testing in primary care (MIB81)

    NICE has developed a medtech innovation briefing (MIB) on the Alere Afinion CRP for C-reactive protein testing in primary care

    Medtech innovation briefing
    Published
    14 September 2016

  9. Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912]

    Awaiting development Reference number: GID-TA10797 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. NY-ESO-1 T-cells for treating synovial sarcoma ID1286

    In development Reference number: GID-TA10205 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]

    In development Reference number: GID-TA10223 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]

    In development Reference number: GID-TA10248 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Talacotuzumab for untreated acute myeloid leukaemia [ID1262]

    In development Reference number: GID-TA10249 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]

    In development Reference number: GID-TA10251 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]

    In development Reference number: GID-TA10225 Expected publication date: TBC

    Technology appraisal guidance
    In development